Cargando…
Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to su...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317210/ https://www.ncbi.nlm.nih.gov/pubmed/30622437 http://dx.doi.org/10.1186/s12935-018-0719-4 |
_version_ | 1783384707184984064 |
---|---|
author | van Vuuren, Rustelle Janse Botes, Mandie Jurgens, Tamarin Joubert, Anna Margaretha van den Bout, Iman |
author_facet | van Vuuren, Rustelle Janse Botes, Mandie Jurgens, Tamarin Joubert, Anna Margaretha van den Bout, Iman |
author_sort | van Vuuren, Rustelle Janse |
collection | PubMed |
description | BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to subcellular locations including the focal adhesions. In fact, focal adhesion dynamics and cell migration are in part regulated by microtubules. We hypothesised that novel 2ME2 derivatives can alter cell migration by influencing microtubule dynamics in interphase cells. In this report we describe 2ME2 derivatives that display anti-migratory capabilities in a metastatic breast cancer cell line through their effects on the microtubule network resulting in altered focal adhesion signalling and RhoA activity. METHODS: Cell migration was assayed using wound healing assays. To eliminate mitosis blockage and cell rounding as a confounding factor cell migration was also assessed in interphase blocked cells. Fluorescence confocal microscopy was used to visualise microtubule dynamics and actin cytoskeleton organisation while western blot analysis was performed to analyse focal adhesion signalling and RhoA activation. RESULTS: 2ME2 derivatives, ESE-one and ESE-15-one, inhibited cell migration in cycling cells as expected but equally diminished migration in cells blocked in interphase. While no significant effects were observed on the actin cytoskeleton, focal adhesion kinase activity was increased while RhoA GTPase activity was inhibited after exposure to either compound. Microtubule stability was increased as evidenced by the increased length and number of detyrosinated microtubules while at the same time clear disorganisation of the normal radial microtubule organisation was observed including multiple foci. CONCLUSIONS: ESE-15-one and ESE-one are potent migration inhibitors of metastatic breast cancer cells. This ability is coupled to alterations in focal adhesion signalling but more importantly is associated with severe disorganisation of microtubule dynamics and polarity. Therefore, these compounds may offer potential as anti-metastatic therapies. |
format | Online Article Text |
id | pubmed-6317210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63172102019-01-08 Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization van Vuuren, Rustelle Janse Botes, Mandie Jurgens, Tamarin Joubert, Anna Margaretha van den Bout, Iman Cancer Cell Int Primary Research BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to subcellular locations including the focal adhesions. In fact, focal adhesion dynamics and cell migration are in part regulated by microtubules. We hypothesised that novel 2ME2 derivatives can alter cell migration by influencing microtubule dynamics in interphase cells. In this report we describe 2ME2 derivatives that display anti-migratory capabilities in a metastatic breast cancer cell line through their effects on the microtubule network resulting in altered focal adhesion signalling and RhoA activity. METHODS: Cell migration was assayed using wound healing assays. To eliminate mitosis blockage and cell rounding as a confounding factor cell migration was also assessed in interphase blocked cells. Fluorescence confocal microscopy was used to visualise microtubule dynamics and actin cytoskeleton organisation while western blot analysis was performed to analyse focal adhesion signalling and RhoA activation. RESULTS: 2ME2 derivatives, ESE-one and ESE-15-one, inhibited cell migration in cycling cells as expected but equally diminished migration in cells blocked in interphase. While no significant effects were observed on the actin cytoskeleton, focal adhesion kinase activity was increased while RhoA GTPase activity was inhibited after exposure to either compound. Microtubule stability was increased as evidenced by the increased length and number of detyrosinated microtubules while at the same time clear disorganisation of the normal radial microtubule organisation was observed including multiple foci. CONCLUSIONS: ESE-15-one and ESE-one are potent migration inhibitors of metastatic breast cancer cells. This ability is coupled to alterations in focal adhesion signalling but more importantly is associated with severe disorganisation of microtubule dynamics and polarity. Therefore, these compounds may offer potential as anti-metastatic therapies. BioMed Central 2019-01-03 /pmc/articles/PMC6317210/ /pubmed/30622437 http://dx.doi.org/10.1186/s12935-018-0719-4 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research van Vuuren, Rustelle Janse Botes, Mandie Jurgens, Tamarin Joubert, Anna Margaretha van den Bout, Iman Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title | Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title_full | Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title_fullStr | Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title_full_unstemmed | Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title_short | Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
title_sort | novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317210/ https://www.ncbi.nlm.nih.gov/pubmed/30622437 http://dx.doi.org/10.1186/s12935-018-0719-4 |
work_keys_str_mv | AT vanvuurenrustellejanse novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization AT botesmandie novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization AT jurgenstamarin novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization AT joubertannamargaretha novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization AT vandenboutiman novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization |